Abstract: The present disclosure relates to compounds that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging; wherein the inhibitors of NLRP3 inflammasomes are compounds of Formula VII: or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
September 9, 2022
Date of Patent:
July 25, 2023
Assignee:
BIOAGE LABS, INC.
Inventors:
George Hartman, Paul Humphries, Kevin Edward Leif Wilhelmsen
Abstract: The present disclosure relates to compounds of Formula I: that act as inhibitors of NLRP3 inflammasomes; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with inflammation and inflammaging, including hearing loss and other diseases associated with aging.
Type:
Grant
Filed:
March 23, 2022
Date of Patent:
July 18, 2023
Assignees:
BIOAGE LABS, INC., HITGEN, INC.
Inventors:
George Hartman, Xu He, Jia Du, Lifang Zhang, Paul Humphries, Kevin Edward Leif Wilhelmsen
Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.
Abstract: The present invention provides soluble RAGE-Fc fusion proteins with increased stability and extended half-life capable of binding endogenous RAGE ligands with high apparent affinity. The present invention also provides methods of making and using stable, soluble RAGE-Fc fusion proteins. These soluble RAGE-Fc fusion proteins are useful as therapeutics based on their ability to bind endogenous RAGE ligands.
© 2025 Justia
